The Impact of Charlson Comorbidity Index on Mortality From SARS-CoV-2 Virus Infection.
charlson comorbidity index
colacd
covid-19
impact
mortality
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
24
11
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
4
1
2022
Statut:
epublish
Résumé
Charlson Comorbidity Index (CCI) is a simple, validated, and readily acceptable method of determining the risk of mortality from comorbid disease. It has been used as a predictor of long-term survival and prognosis. The aim of this study is to determine the impact of CCI score on mortality in COVID-19 hospitalized patients and test the efficacy of the CoLACD score (COVID-19 lymphocyte ratio, age, CCI score, dyspnoea) in predicting mortality among hospitalized COVID-19 patients. It was a retrospective cohort, and the data of this study were gathered from two tertiary hospitals of Karachi, including Liaquat National Hospital and Ziauddin Hospital. Data of patients hospitalized in any of these tertiary care hospitals and diagnosed with confirmed COVID-19 infection were used in the study from January 15, 2021, to April 30, 2021. The mean age of participants was 53.22 (±14.21) years. The majority of participants were males (74.91%). Predictors of mortality include CCI score, age of participants, D-dimer, smoking status, and shortness of breath. The sensitivity of this CoLACD score was 80.23%, and specificity was 50.23% (diagnostic accuracy is 60.45%). The negative predictive value (NPV) of this test was 39.44%, and the positive predictive value (PPV) was 83.01%. Our study showed that CCI can be used in a clinical setting to achieve a prediction of mortality in COVID-19 patients.
Identifiants
pubmed: 34976530
doi: 10.7759/cureus.19937
pmc: PMC8711750
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Pagination
e19937Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2021, Ahmed et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Infect Dis. 2020 Jul 28;71(15):833-840
pubmed: 32296824
Psychiatry Res. 2020 Nov;293:113419
pubmed: 32861098
J Popul Ther Clin Pharmacol. 2019 Dec 27;26(4):e37-e53
pubmed: 31909577
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Am J Emerg Med. 2021 Aug;46:204-211
pubmed: 33071085
Scand J Trauma Resusc Emerg Med. 2020 Jul 13;28(1):66
pubmed: 32660623
J Intern Med. 2020 Oct;288(4):469-476
pubmed: 32498135
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Int J Clin Pract. 2021 Apr;75(4):e13858
pubmed: 33237615
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Gen Intern Med. 2020 Sep;35(9):2801-2803
pubmed: 32583345